Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for anemia in chronic kidney disease (Study B)
jRCTs041200108Recruiting
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dapagliflozin in chronic kidney disease (CKD), anemia of chronic kidney disease, type 2 diabetes mellitus (T2DM) and 1 more. Primary endpoint: Time to first event of Hb <10.5 g/dL or initiation of ESA. Started May 2021; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)anemia of chronic kidney diseasetype 2 diabetes mellitus (T2DM)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on jRCTs041200108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200108.